利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.024 秒)

    THERAPEUTIC USE OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTITUMORAL DRUGS BOUND TO HYALURONIC ACID IN THE TREATMENT OF NEOPLASIAS
    2.
    发明申请
    THERAPEUTIC USE OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTITUMORAL DRUGS BOUND TO HYALURONIC ACID IN THE TREATMENT OF NEOPLASIAS 有权
    在治疗NEOPLASIAS中治疗含有抗高血压药物的抗药物的新药物制剂的治疗应用

    公开(公告)号：US20110189265A1

    公开(公告)日：2011-08-04

    申请号：US12988630

    申请日：2009-04-21

    申请人： Monica Campisi ,  Davide Renier ,  Pasquale Pierimarchi ,  Annalucia Serafino

    发明人： Monica Campisi ,  Davide Renier ,  Pasquale Pierimarchi ,  Annalucia Serafino

    IPC分类号： A61K9/127 ,  A61K47/48 ,  A61P35/00 ,  A61P35/04

    CPC分类号： A61K47/61

    摘要： The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behaviour is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.

    摘要翻译： 本发明描述了在生物缀合物的肿瘤领域中的新用途，其作为通过透明质酸（HA）和化学治疗产品（以下称为商品名ONCOFID）之间缀合获得的分化剂），其中尤其是伊立替康，多柔比星 ，紫杉醇，顺铂和5-氟尿酰基（5-FU）用于治疗原发性肿瘤和转移。 特别地，根据可溶于水的ONCOFID的衍生物的药物制剂的作用机制，功效和耐受性来描述生物学行为。 更具体地，本发明涉及通过基于ONCOFID-S（HA-SN38缀合物）和ONCOFID-D（HA-多柔比星缀合物）的制剂在促进肿瘤细胞向未转化表型的分化中所证明的令人惊奇的生物学和药理作用， 参考药物伊立替康（或活性形式由SN38代表的CPT11）和多柔比星。

    Process for preparing a hyaluronic acid fraction having a low polydispersion index
    6.
    发明授权
    Process for preparing a hyaluronic acid fraction having a low polydispersion index 失效
    具有低多分散指数的透明质酸级分的制备方法

    公开(公告)号：US6020484A

    公开(公告)日：2000-02-01

    申请号：US96646

    申请日：1998-06-12

    申请人： Lanfranco Callegaro ,  Davide Renier

    发明人： Lanfranco Callegaro ,  Davide Renier

    IPC分类号： C08B37/08 ,  C07H1/00

    CPC分类号： C08B37/0072

    摘要： A process for preparing a hyaluronic acid fraction having an average molecular weight comprised between 5000 and 300,000 and a polydispersion index lower than 1.7, comprising treating the starting high molecular weight hyaluronic acid, contemporaneously with sodium hypochlorite and ultrasounds.

    摘要翻译： PCT No.PCT / EP96 / 05701 Sec。 371日期：1998年7月12日 102（e）1998年7月12日PCT 1996年12月19日PCT PCT。 公开号WO97 / 22629 日期1997年6月26日制备平均分子量为5000〜300000，多分散指数低于1.7的透明质酸级分的方法，其包括用次氯酸钠和超声波同时处理起始高分子量透明质酸。

    Electrically conductive polymeric biomaterials, the process for their preparation and the use thereof in the biomedical and healthcare field
    10.
    发明授权
    Electrically conductive polymeric biomaterials, the process for their preparation and the use thereof in the biomedical and healthcare field 有权
    导电聚合物生物材料，其制备方法及其在生物医学和保健领域的应用

    公开(公告)号：US07253152B2

    公开(公告)日：2007-08-07

    申请号：US10476854

    申请日：2002-04-29

    申请人： Stefania Panero ,  Gianluca Abbati ,  Davide Renier ,  Vittorio Crescenzi

    发明人： Stefania Panero ,  Gianluca Abbati ,  Davide Renier ,  Vittorio Crescenzi

    IPC分类号： A01N43/04 ,  A61K31/715 ,  C07H1/00

    CPC分类号： A61L27/50 ,  A61L27/48 ,  C08L39/06

    摘要： The present invention concerns the preparation of composite biomaterials constituted by hyaluronic acid and the derivatives thereof in combination with polymers that have electrically conductive properties. In particular, the methods of preparing biomedical devices formed by a two- or three-dimensional polysaccharide matrix and by an electrically conductive membrane. The matrix is constituted by hyaluronic acid derivatives in the form of membranes, woven fabrics, nonwoven felts, meshes, gauzes, guide channels or sponges, while the electrically conductive membrane is constituted by a film of polypyrrole (polymer conductor) in combination with hyaluronic acid or a derivative thereof (doping agent).

    摘要翻译： 本发明涉及由透明质酸及其衍生物与具有导电性质的聚合物组合构成的复合生物材料的制备。 特别是制备由二维或三维多糖基质和导电膜形成的生物医学装置的方法。 该基质由膜，机织织物，非织造毡，网状物，纱布，引导通道或海绵形式的透明质酸衍生物构成，而导电膜由聚吡咯（聚合物导体）与透明质酸组合 或其衍生物（掺杂剂）。